First-pass extracted concept

CRISPR-Cas9 or base editing gene editing strategies for hemoglobinopathies

Candidate: concept label1 source documents3 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Evidence Snippets

the other based on gene editing strategies using CRISPR-Caspase 9 technology or base editing

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2025MEDDOI PubMed

1 evidence snippet 3 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1approach classificationsupports2025Source 1DOI PubMed

The review describes two gene therapy approach classes for hemoglobinopathies: lentiviral gene addition or gene silencing, and gene editing using CRISPR-Cas9 or base editing.

Claim 2clinical outcome summarysupports2025Source 1DOI PubMed

Several gene therapy products for sickle cell disease and beta-thalassemia have been successfully evaluated, achieving transfusion independence and durable correction of hematological abnormalities.

Claim 3regulatory status summarysupports2025Source 1DOI PubMed

Several gene therapy products have been approved for treatment of sickle cell disease and beta-thalassemia and offer potentially curative treatment.